This contrasts with targets in prior nanobody design studies [Bennett et al., 2025, Mille-Fragoso et al., 2025], which were selected for therapeutic relevance rather than novelty and have appeared in a bound context in the PDB at least once, exhibiting highly similar bound interfaces (Figure 2c)
XTALKS WEBINAR: Sarcopenia: Changes and Challenges in Body Composition with GLP-1 Receptor Agonist-based Weight Loss Therapies Live and On-Demand: Friday, September 6, 2024 , at 10am EDT (4pm CEST / EU-Central) Register for this free webinar to learn about the latest clinical trial data on GLP-1 receptor agonist-based therapies and their impact on weight loss and body composition
Chen, K., Zheng, X., Feng, M., Li, D., & Zhang, H
Thus we recently investigated the effects of triheptanoin in the hSOD1 G93A mice (Tefera et al., 2016)
IGF-1 LR3 compared with IGF-1 DES IGF-1 LR3 is often compared with IGF-1 DES, but they are different research compounds
Its important for LHON patients to talk to their doctors